Intelligence · Clinical pipeline
Oncology R&D Pipeline
Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Quick answer
Oncology: NovaPharmaNews indexes 5,539 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.
Top sponsors
- First People's Hospital 474 programs
- Chinese Academy of 400 programs
- United Therapeutics Europe 219 programs
- George Institute for 172 programs
- Takeda 163 programs
- HOFFMANN-LA ROCHE 144 programs
- AstraZeneca 143 programs
- MSD Merck Sharp 131 programs
- Regeneron UK 128 programs
- Anaxis Pharma 125 programs
- Telethon Foundation 113 programs
- Novartis India 110 programs
Pipeline programs
-
APR-246
Aprea Therapeutics
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
1 trial -
APR-246
Aprea Therapeutics
Acute Myeloid Leukemia or Myelodysplastic Syndromes
1 trial -
APR-246
Aprea Therapeutics
High-grade Serous Ovarian Cancer
1 trial -
APR-246
Aprea Therapeutics
Melanoma
1 trial -
APR-246 (eprenetapopt) + Acalabrutinib in CLL
Aprea Therapeutics
Non Hodgkin Lymphoma
1 trial -
APR-246 (eprenetapopt) + Pembrolizumab
Aprea Therapeutics
Bladder Cancer
1 trial -
APX005M
Pyxis Oncology
Melanoma
1 trial -
ARC-21(EDGE-Gastric)
Arcus Biosciences
Upper Gastrointestinal Tract Cancer, Advanced Upper Gastrointestinal Tract Malignancies, Gastrointestinal Tract Malignancies
1 trial -
ARC-9
Arcus Biosciences
Metastatic colorectal cancer
1 trial -
ARD6122
Regeneron UK Limited
Neoplasms
1 trial -
ARI-HER2
The George Institute
Patients with HER2Positive Advanced Breast Cancer
1 trial -
ART27.13-100
ARTELO BIOSCIENCES, INC.
Cancer Anorexia
1 trial -
ART6043C001
Lacuna Pharma Pty Ltd
Metastatic solid tumors, Advanced solid tumors
1 trial -
ASCAPE-based follow-up strategy
ATOSSA THERAPEUTICS, INC.
Breast Cancer
1 trial -
ASLAN001
Hospital Authority, Hong Kong
Advanced/ Metastatic Hepatocellular Carcinoma
1 trial -
ASND0029
Lacuna Pharma Pty Ltd
Locally advanced or metastatic solid tumor malignancies, platinum resistant ovarian cancer, post-anti-pd-1 melanoma, second line or later cervical cancer, neoadjuvant melanoma and neoadjuvant non-small cell lung cancer, post-anti-pd-L1 non-small cell lung cancer, post-anti-pd-L1 small cell lung cancer, second line or later HER2+ breast cancer
1 trial -
ASND0038
Lacuna Pharma Pty Ltd
Stage III-IVA Resectable Locoregionall Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
1 trial -
ASP3082, DEXTROSE INJECTION / BRADEX 5%
The George Institute
Metastatic Non-small cell lung cancer (NSCLC) and Pancreatic ductal adenocarcinoma
1 trial -
ASP8273
Astellas Pharma Inc
Non-small Cell Lung Cancer
1 trial -
ASPIRE
The George Institute
Patients with resectable hepatocellular carcinoma (amenable R0 resection) at high risk of recurrence.
1 trial -
ASTX727
Taiho Pharma Netherlands B.V.
Acute myeloid lymphoma (AML), myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML) or solid tumors
1 trial -
ASTX727-07
Taiho Pharma Netherlands B.V.
Acute Myeloid Leukemia (AML)
1 trial -
AT148009
ALX ONCOLOGY HOLDINGS INC
Breast Cancer
1 trial -
ATEZOLIZUMAB
The George Institute
Patients with metastatic tumours (colorectal, non-small cell lung, renal and sarcoma)
1 trial -
ATRN-119
Aprea Therapeutics
HPV Positive Oropharyngeal Squamous Cell Carcinoma
1 trial -
ATRN-119
Aprea Therapeutics
Advanced Solid Tumor
1 trial -
AU-011
Aura Biosciences
Eye Cancer
1 trial -
AU-011
Aura Biosciences
Uveal Melanoma
1 trial -
AUR103 Calcium
Disc Medicine
HER 2 Positive Gastric Cancer
1 trial -
AUTO1
Autolus GmbH
Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
2 trials -
AUTO3
Autolus GmbH
Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
1 trial -
AUTO3 (CD19/22 CAR T cells
Autolus GmbH
B Acute Lymphoblastic Leukemia
1 trial -
AUTO4
Autolus GmbH
T Cell Non-Hodgkin Lymphoma
1 trial -
AUY922
Novartis Pharmaceuticals
Advanced HER2-positive Breast Cancer
1 trial -
AUY922
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Gastrointestinal Stromal Tumor
1 trial -
AVELUMAB, Erbitux 5 mg/mL solution for infusion
Fondazione Telethon ETS
recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
1 trial -
AVN944
Vertex Pharmaceuticals (Australia) Pty.
Pancreatic Cancer
1 trial -
AZD0486, AZD0486
AstraZeneca AB
Relapsed or Refractory Non-Hodgkin Lymphoma
1 trial -
AZD2014
Samsung Bioepis NL B.V.
Cancer of Stomach
1 trial -
AZD2265 (FPI-2265)
AstraZeneca
Metastatic Prostate Cancer
1 trial -
AZD2281
AstraZeneca
Ovarian Neoplasms
1 trial -
AZD4360
AstraZeneca AB
Gastric Cancer, Gastroesophageal Junction Cancer, Biliary Tract Cancer, Pancreatic Ductal Adenocarcinoma
1 trial -
AZD4512
AstraZeneca AB
B-cell acute lymphoblastic leukemia (B-ALL)
1 trial -
AZD4512
AstraZeneca AB
Non-Hodgkin lymphoma (NHL)
1 trial -
AZD5069
United Therapeutics Europe Ltd
Metastatic Castration Resistant Prostate Cancer
1 trial -
AZD5363
United Therapeutics Europe Ltd
Adenocarcinoma of the Prostate
1 trial -
AZD5363
Cardiff Oncology
Estrogen Receptor Positive Breast Cancer
1 trial -
AZD5363 when combined with weekly paclitaxel.
AstraZeneca
Advanced or Metastatic Breast Cancer
1 trial
Frequently asked questions
How many oncology pipeline programs are tracked?
5,539 programs match this therapeutic area based on indication text, program name, and registry metadata.
Where does pipeline data come from?
ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.